Cancer and electrolytes imbalance

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 6, 2010, Pages 1006-1010

  Shibata, Hiroyuki ^a  

^a AKITA UNIVERSITY   (Japan)

Author keywords

Hypercalcemia; Hyperkalemia; Hypomagnesemia; Hyponatremia

Indexed keywords

ABL KINASE INHIBITOR; ANTINEOPLASTIC AGENT; CALCIUM; CETUXIMAB; MAGNESIUM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANITUMUMAB; PHOSPHATE; POTASSIUM; SODIUM; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG TARGETING; ELECTROLYTE DISTURBANCE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPOMAGNESIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; MAGNESIUM BLOOD LEVEL; OSTEOLYSIS; PARANEOPLASTIC SYNDROME; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PROSTATE CANCER; SODIUM BLOOD LEVEL; TUMOR LYSIS SYNDROME;

EID: 79960774488     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350:1655-1664,2004.
2. Wysolmerski JJ and Broadus AE: Hypercalcemia of malignancy: The central role of parathyroid hormone-related protein. Ann Rev Med 45:189-200,1994.
3. Payne RB, Carver ME and Morgan DB: Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 32:56-60,1979. (Pubitemid 9108607)
4. Jüppner H, Abou-Samra AB, Freeman M, et al: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024-1026,1991.
5. Seymour JF and Gagel RF: Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82:1383-1394,1993. (Pubitemid 23263952)
6. Hurtado J and Esbrit P: Treatment of malignant hypercalcemia. Expert Opin Pharmacother 3:521-527,2002.
7. Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to Pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567,2001. (Pubitemid 32112871)
8. Clezardin P: Anti-tumour activity of zoledronic acid. Cancer Treatment Rev 31(suppl 3):1-8,2005.
9. Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623-633,2004. (Pubitemid 39578752)
10. Annemans L, Moeremans K, Lamotte M. et al: Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 11:249-257,2003. (Pubitemid 36723571)
11. Bevilacqua M: Hyponatraemia in AIDS. Baillieres Clin Endocrinol Metab 8:837-848,1994.
12. Raftopoulos H: Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 15:1341-1347,2007.
13. Heasley LE: Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20:1563-1569,2001.
14. Decaux G, Soupart A and Vassart G: Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624-1632,2008.